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 Clinical and cost-effectiveness of cognitive behaviour therapy for health anxiety in medical 
patients  
 
Abstract 
Background 
 
Health anxiety, commonly called hypochondriasis but having a broader definition, has been 
treated by therapists expert in cognitive behaviour therapy (CBT) with some specific benefit 
in some patients. Those in hospital care have been less often investigated.  Following a pilot 
trial suggesting efficacy we carried out a randomized study in hospital medical clinics.  
Methods 
We undertook a multicenter, randomised trial on health anxious patients attending out-
patient clinics in secondary care.  A computer-generated random scheme was used to 
allocate eligible medical patients to an active treatment group of 5-10 sessions of adapted 
CBT (CBT-HA) delivered by hospital-based therapists or to standard care in the clinics.  The 
primary outcome was change in health anxiety symptoms measured by the Health Anxiety 
Inventory at one-year and the main secondary hypothesis was equivalence of total health 
and social care costs over two-years, with an equivalence margin of £150. Analysis was by 
intention to treat. The study is registered as ISRCTN14565822. 
Findings 
Findings 
Of 28,991 patients screened, 219 were randomly assigned to  CBT-HA and 225 to a standard 
care arm. 205 and 212, respectively, were included in the analyses of the primary endpoints.  
At one-year, improvement in health anxiety in CBT-HA patients was 2.98 points greater than 
in the standard care group (95% confidence interval [CI], 1.64 to 4.33, P<0.001). Twice as 
many patients receiving CBT achieved normal levels of health anxiety compared to the 
control group (13.9% vs 7.3%).  Similar differences were observed at six months and two 
years, and there were concomitant reductions in generalized anxiety and, to a lesser extent,  
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depression. There were no significant differences in social functioning or health-related 
quality of life. Despite e. Equivalence in total two-year costs was not being achieved, but the 
difference was not statistically significant (adjusted mean difference £156, 695% CI -£1,446 
to £1,758 to £446, p=0.848) (95% CI -£1,758$1143 to 446$940, p=0.848.  
 
Interpretation 
 
This form of adapted CBT for health anxiety led to sustained symptomatic benefit over a 
two-year period, with no significant impact on total costs. with treatment costs offset by 
savings elsewhere.   It deserves wider application in medical care.  
Funded by the U.K. National Institute of Health Research Health Technology Assessment 
Programme. Current Controlled Trials number ISRCTN14565822  
 
Introduction 
Health anxiety, together with its approximate synonym, hypochondriasis, is a common 
problem in the community (life-time prevalence 5%),1, and in both primary and secondary  
care. 2-4. It places a substantial burden on health services5 as the fear of having a serious 
disease leads to medical consultation, commonly followed by further investigations.  
Pathological health anxiety provokes considerable suffering but often goes unrecognised or 
appreciated only at a superficial or even comical level. Even when recognised, expensive 
investigations may be carried out unnecessarily because of fear of litigation.  In general 
hospitals, between 10 and 20% of all attenders have abnormal health anxiety and this is 
often undetected as many patients have a history of previous medical illnesses so that their 
anxiety is seen as reasonable and proportionate. Patients often rotate between different 
clinics depending on the focus of their symptoms. Often symptoms last for years and show 
little tendency to spontaneous resolution. Psychological treatment in the form of cognitive 
behaviour therapy (CBT) delivered by expert therapists is of proven effectiveness for anxiety 
disorders;6; its application to health anxiety has been shown to be effective relative to both 
waitlist and comparison psychological treatments. These studies were conducted mainly in 
primary and psychiatric care7-9 with specialist therapists. In a pilot study carried out by our 
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group, More recently these results have been shown to generalise to secondary medical 
care settings (where costs of care are high) using less expert therapists trained for the 
purpose. 10. The CHAMP (cognitive behaviour therapy for health anxiety in medical patients) 
trial was subsequently set up to examine both efficacy and cost-effectiveness of a modified 
cognitive behavioural treatment for health anxiety (CBT-HA) with assessment of outcomes 
over a two-year period.   
 
Methods 
 
CHAMP was a pragmatic randomized controlled trial with two parallel arms and equal 
randomization of eligible patients initially to 5-10 sessions of CBT-HA or to standard care in 
the clinics. Assessments of health anxiety, generalised anxiety, depression, social function, 
quality of life and costs were made over a two year period after randomization. The primary  
outcome was symptoms of health anxiety after one year. Those allocated to CBT-HA were 
treated by graduate research workers, nurses or other health professionals trained for this 
intervention. Our two main hypotheses, based upon the results of our pilot study,10 were 
that (i) patients offered between 5 and 10 sessions of cognitive behaviour therapy focused 
on health anxiety, CBT-HA,11 in addition to standard care would have lower levels of health 
anxiety measured by the Health Anxiety Inventory (HAI)12 one year after randomiszation to 
the trial than those treated with standard care alone, and (ii)  from a the overall health and 
social care perspective, the costs of the CBT-HA and standard groups would be equivalent at 
2 years (i.e. costs of CBT-HA would be offset by savings in other areas).  
Secondary hypotheses were that health anxiety at other time points, generalised anxiety 
and depression, social functioning and quality of life measured by standard measures13-15 
would differ between CBT-HA and standard care and that CBT-HA would be a cost-effective 
use of resources.  
 
Randomisation and masking 
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Eligible patients in whom consent was provided were allocated in a 1:1 ratio to the two 
arms of the study according to a computer-generated random sequence using block 
randomisation with varying blocksize of four and six. The allocation sequence was not 
available to any member of the research team until databases had been completed and 
locked.   
  
Settings and procedure 
Patients attending cardiology, endocrine, gastroenterology, neurology and respiratory 
medicine clinics, where health anxiety prevalence was known to be high,4, in six general 
hospitals in the UK were considered for the study.  All patients attending clinics of the 
collaborating consultants, apart from the specific exclusions below, were approached while 
waiting for their out-patient appointments and, after consent,  given the short form of the 
HAI,12, a self-rating scale of 14 questions that takes 5-10 minutes to complete. Those that 
scored 20 or more on the scale, an accepted cut-off point,12, were given a brief summary of 
the trial and offered the opportunity of further assessment, and, if they were interested, 
were then given an information sheet about the study.  Those that agreed in principle to 
take part were then asked the questions in the Structured Clinical Interview for DSM-IV16 
covering the diagnosis of hypochondriasis, all of which had to be answered positively to 
confirm the diagnosis. Those that satisfied the diagnosis of hypochondriasis were asked for 
written consent to take part and baseline assessments completed. This, through necessity, 
involved a standard explanation of the nature and significance of health anxiety and so 
constituted a small intervention in all patients who entered the trial.  
After baseline assessment, randomization was carried out by an independently operated 
computerised system (using block randomization with no stratification in randomized blocks 
of four and six).  
Interventions 
Each patient in the CBT-HA arm of the trial was offered between 5 and 10 sessions of 
treatment initially but booster sessions were also allowed. Each therapist was supervised at 
2-4 week intervals at least (by HS, GS, EM and SF) during treatment to ensure consistency in 
treatment.  Bias in follow-up assessments was reduced by replacing the research assessor 
with another research assistant if at any time they were unwittingly informed about the 
patient’s allocation status.  
 
Training and Fidelity of Intervention 
 
Four collaborators (PS, GS, EM, and HS) trained the therapists at two workshops and also 
assessed treatment fidelity, together with HW. 50% of all treatment sessions were audio 
recorded. Fidelity was tested using the health anxiety modification of the Cognitive Therapy 
Rating Scale17 (CTRS-HAV). 17  Recordings were assessed by the local supervisor and a 
random sample sent to a supervisor at a different site to assess the level of agreement, with 
further training ending only when an agreement level of 0.80 kappa was reached.  
The study was approved by the North Nottingham Ethics Committee (08/H0403/56) prior to 
the start of data collection. 
 
Inclusion and exclusion criteria 
 
Those who satisfied the criteria for excessive health anxiety above were included if they 
were (i) aged between 16 and 75, (ii) permanently resident in the area, (iii) had sufficient 
understanding of English to read and complete study questionnaires, and (iv) gave written 
consent for the interviews, audio-taping of 50% of treatment sessions, and for access to 
their medical records. The presence of existing medical pathology, provided it was not a 
new diagnosis requiring further investigation, was not a study exclusion criterion.  Those 
that were felt by their consultants to have a level of continuing major pathology that was 
too severe for them to take part in the study, including progressive cognitive impairment, 
terminal disorders, and any major comorbid pathology that would interfere with 
psychological treatment, those who were currently being actively investigated for significant 
pathology suspected by the clinician and for whom cognitive behaviour therapy might 
confuse or cause distress, and those currently under psychiatric care were also excluded. 
 
Assessments of health anxiety (HAI),12, anxiety and depression (HADS),13, health-related 
quality of life (EQ-5D),14, and social function (SFQ)15 were made at baseline and assessed 
independently by research assistants at 6m, 12m and 2 years.  Health anxiety scores (HAI) 
were additionally recorded at 3 months. Service use data for the economic evaluation were 
collected at baseline, 6m, 12m and 2-year follow-ups using the Adult Service Use Schedule 
(AD-SUS), a self-report instrument assessed in interview and designed on the basis of 
previous economic evaluations in adult mental health populations,18, and also by 
examination of computerised hospital records. AD-SUS data were recorded at baseline, 6m, 
12m and 2-year follow-ups. Where AD-SUS data conflicted with the data obtained from 
records, the computerised records took precedence.  
 
Statistical analysis  
A sample size of 122 patients per group was needed to detect a CBT-HA/standard care score 
difference of 5.00 points 10 with 95% power at a two -sided 5% significance level assuming 
that the standard deviation for the change of HAI at 1 -year is 7.58 points. Taking into 
account a possible rate of drop-out of 20% at 12 months, the estimated sample size was 152 
patients. We also did a sample size calculation to demonstrate equivalence between CBT-HA 
and control in the main secondary outcome (total costs over 24-months) using data from 
the pilot study and with the hypothesis that over a longer follow-up the reductionsevidence 
of lower total in costs in the CBT-HA group seen in the pilot study would, over a longer 
follow-up, offset the cost of the therapy.10. Assuming that the expected difference in mean 
cost is nil and the common standard deviation is £580, a sample size of 186 per group would 
have 80% power to declare that the cost of the CBT-HA and control groups were equivalent 
with a pre-specified equivalence margin of £150.10 Equivalence would be declared if the 
95% confidence interval falls within -£15097.50 and £150.  Assuming a 20% dropout by 24 
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months, 466 patients needed to be recruited. The main analysis was based on the intention-
to-treat principle.  
 
The primary endpoint was analysed using a mixed model with time, treatment, and time x 
treatment interaction as fixed effects, baseline measurement as covariate, and patient as 
random effect. The treatment differences at each time point including 12 months, together 
with its 95% confidence interval, were derived from the mixed model.  
 
Missing data were treated as missing at random in the above mixed model analysis. To 
assess the sensitivity of the result to this assumption, the last observation carried forward 
(LOCF) strategy was used to compute the missing HAI at during the follow up visits. Other 
assessments were analysed in a similar way. In addition, covariate-adjusted analysis was 
performed on the primary outcome analysis by mixed model controlling for 3 pre-specified 
potential predictors for primary endpoint (clinical type, site and age). 
Nationally applicable unit costs were applied to all elements of service use collected in the 
AD-SUS and from computerised hospital records,19-21, including the cost of CBT., although 
this However, the cost of CBT was adjusted to reflect the salaries of the CBT-HA therapists 
employed in the study (). All unit costs were calculated and analysed in UK Pound Sterling 
for the financial year 2008-2009 but are presented as international dollars using a 
conversion rate of 0.65 (www.eppi.ioe.ac.uk/costconversion). Costs in the second year were 
discounted at a rate of 3.5%, as recommended by the National Institute for Health and 
Clinical Excellence.22.  
The economic evaluation included those patients for whom complete data at baseline, 12 
and 24 months follow-up were available, with multiple imputation for missing data tested in 
sensitivity analysis.23 Standard parametric tests were used as recommended for the analysis 
of cost data24 with the robustness of the tests confirmed using bias-corrected, non-
parametric bootstrapping.25 .Details of the cost-effectiveness analysis are in the web 
appendix.  
 
Results 
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28,991 patients were screened during the 21 months of recruitment.  5769 patients (19.9%) 
of these scored 20 or over on the HAI, but many of these refused to take part or were not 
interviewed further for several reasons (Figure 1). This left 445 patients who were 
randomized but as one patient was mistakenly randomized twice, both times to standard 
care, the later set of data was discarded and only 444 were included in the trial (Figure  1).  
There were 9 deaths; 6 in the standard care group and 3 in the CBT-HA group. All deaths 
were due to natural causes in patients with pre-existing medical pathology. The mean 
number of CBT-HA treatment sessions was 6 (range 0-22), with 15 patients receiving no 
treatment. Patients allocated to CBT-HA improved rapidly after treatment and showed 
significantly greater reduction in health anxiety at all assessment points (Figure 2).  These 
differences were highly significant at all assessment points, including at 12 –months, the 
(primary outcome point) (Ddifference=2.98,  95% CI, 1.64 to 4.33, P<0.001). These 
differences were maintained in further analyses with site and baseline scores as covariates. 
At one year, 13.9% of the patients receiving CBT-HA had levels of health anxiety in the 
normal range (HAI score of 10 or less) compared to 7.3% in the control group. The results of 
health anxiety scores remained similar when the LOCF strategy was used to compute the 
missing HAI at during the follow -up visits (Appendix 1). We have also performed covariate 
adjusted analysis and the adjusted treatment effect on the primary endpoint was similar to 
the unadjusted effect (Appendix 2). 
 
Patients in the CBT-HA group showed significantly greater improvement in self-rated anxiety 
and depression symptoms at 6 and 12 months, compared with standard care (Table 2). 
Social functioning and health-related quality of life showed no important change, apart from 
the visual analogue rating of quality of life, that which approached significance in favour of 
CBT-HA at 6 months.   
 
 
Complete data for the economic evaluation were available for 343 patients (77%). We 
excluded one patient from the CBT-HA group who was classified as an outlier as a result of 
substantial hospital contacts due to a number of confirmed physical conditions (total 24-
month cost £97,987 compared to an average per participant of £8,009 (SD 10,418) for the 
total sample of 343), so the analysis is based on 342. We present here the results for our 
main economic hypothesis relating to equivalence of costs; full cost-effectiveness results are 
contained in the web appendix. 
 
Total costs per patient over 24-months follow-up are detailed in Table 3. The mean cost of 
the CBT-HA intervention was £413 421.51 per patient for a mean of 6 sessions (range £0 to 
£2,383). All other categories of cost, including GP contacts and hospital costs, were lower 
for the CBT-HA group than the control group. Total health and social care costs including the 
cost of the intervention were lower in the CBT-HA group (mean £7,314) than the control 
group (£7,727). In analyses adjusted for baseline cost however, the adjusted mean 
difference between the two groups was -£1556 (95% CI -1,446 to 1,758 to 1,447, p=0.848).; 
aAlthough equivalence was not achieved, there is was no evidence that there is of a 
significant difference in cost between the CBT-HA and control groups. Imputation of missing 
data did not alter this finding (adjusted mean difference £113, 95% CI -1,539 to 930, 
p=0.630).  
 
Assessments of the fidelity of therapists’ treatment showed that all except one scored at an 
adequate competence level or higher, and this was confirmed by the independent assessor 
(HW).  The therapist who failed to achieve this level saw five patients. No serious adverse 
events attributable in any way to the trial intervention were identified in the study, but one 
participant in the standard care group made a serious suicide attempt.   
 
 
Discussion 
The results indicate that the previously noted effectiveness of CBT-HA9-10,2628 generalises to 
patients with significant levels of health anxiety in a range of general medical clinics when 
delivered by therapists with little previous CBT experience but specifically trained to deliver 
treatment in these settings. The benefits of treatment CBT-HA in terms of anxiety were 
noted both in the short and longer –term, and were achieved with equivalent no significant 
difference in costs to usual care and with clear evidence of cost-effectiveness, in common 
with a recent paper demonstrating the cost-effectiveness of internet based cognitive 
therapy for health anxiety27. Although equivalence in costs was not demonstrated, full 
economic data were only available for 73% of the required sample, so the study may have 
been underpowered for our cost hypothesis. 
No evidence of the effectiveness of CBT-HA in terms of the secondary outcomes of social 
functioning or quality of life was evident, with a corresponding lack of evidence of cost-
effectiveness in terms of QALYs (see web appendix). This might suggest...    
The findings from this pragmatic trial suggest that staff trained to deliver CBT-HA in medical 
clinics would help to relieve substantially troubling anxiety in a more cost-effective manner, 
compared to current standard approaches, when considering anxiety symptoms, though not 
quality of lifeway than current standard approaches. The finding that benefit was 
maintained over two years also suggests that without such intervention the morbidity of 
health anxiety persists, possibly because it is reinforced by continued reassurance and 
medical investigations. As benefit was still marked after two years long after treatment had 
been completed the long-term savings on health care could be considerable.  
The main strength of the study was the highly robust effect of treatment despite being given 
by relatively inexperienced staff who were trained only for the CBT-HA intervention. This 
suggests that this form of management could be incorporated into medical clinics and be 
administered by trained staff such as cardiac rehabilitation nurses and other specialist staff 
in other medical clinics who treat repeated attenders, many of whom have existing medical 
pathology but who suffer unduly from persistent and unnecessary worry over their health.  
However, inclusion of patients with confirmed, chronic and recurring medical conditions 
may also have been a weakness in relation to our cost hypothesis, since the medical 
interventions received by these patients added to the variability of cost amongst the group 
and thus had a negative impact on the power available to detect equivalence of costs. 
Although it might have been expected that clear savings in costs would have accrued from a 
reduction in health anxiety, total costs reported include the cost of treating existing, chronic 
medical conditions, which may have hindered our ability to detect differences in cost that 
were due to health anxiety alone. 
 The main A further weakness is that most of the patients who were probably potentially 
eligible for the study declined to take part and so the population treated may not be 
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representative. As many people with hypochondriasis and health anxiety attribute their 
bodily symptoms unequivocally to medical pathology2728  and therefore feel that only 
medical expertise can help them, there would need to be a change in attitudes, both from 
staff and patients, before the treatment could be given more widely.  But if change does not 
occur, and standard medical care fails to be aware of health anxiety, an important, largely 
hidden, but eminently treatable, cause of morbidity in medical clinics is likely to persist.   
 
Competing interests 
HW and PS developed CBT-HA. The other authors declare that they have no competing 
interests. 
Authors' contributions 
The trial was initiated by PT and HT, who, with PS, MC, BB, SB, DM, SD, JG and SR, designed 
the structure of the trial. DW, BB and SB were involved in developing the statistical analysis 
plan, statistical analysis and results interpretation, and HP, BB and SB carried out the 
economic analyses. HT, SF, EM, and GS were therapy supervisors, HT, EM, GS, SF and HW 
checked fidelity of treatment, SC was the trial coordinator and organiser of the recruitment 
strategy. Aaron Beck, MD, acted as trial adviser.  All authors read and approved the final 
manuscript. 
Acknowledgements 
This research was funded by the National Coordinating Centre for Health Technology 
Assessment (NCCHTA) programme (project number 07/01/26.  The views expressed in this 
publication are those of the authors and do not necessarily reflect those of the HTA 
programme, NIHR, NHS, or the Department of Health. We particularly thank the North 
London and East Midlands hubs of the Mental Health Research Network, for adopting, 
promoting and aiding recruitment in the trial. We thank Professor Aaron T Beck for acting as 
adviser to the CHAMP project, Professor Gene Paykel ((chair) and other members of the 
Data Monitoring and Ethical Committee and Professor Richard Mayou (chair) and other 
members of the Trial Steering Committee, the many therapists who provided the treatment, 
Jayne Morton, Kevin Connolly and Gail Marcuson for advice over approaching patients in 
the study,  Sharandeep Bhogal, Faye Cooper, Rachel Evered ,  Mary Keeling, Stephanie Kings,  
Kofi Kramo, Gemma Loebenberg, , Antionette McNulty, Amy Murphy, Jessica Nagar, Sandra 
O’Sullivan,  Rahil Sanatinia,  Richard Seivewright , Carol Sherwood, Julie Sinclair,  David 
Trevor , Gemma Walker and Charlotte Watson in their roles as research assistants and 
supervisors in the study, and the 107 consultants who supported the study from its onset.  
References 
1. Sunderland M, Newby JM, Andrews G. Health anxiety in Australia: prevalence, 
comorbidity, disability and service use. Br J Psychiatry 2013 ;202:56-61. 
2. Escobar JI, Gara M, Waitzkin H, Silver RC, Holman A, Compton W:   DSM-IV 
hypochondriasis in primary care. Gen Hosp Psychiatry 1998,  20: 155-9. 
3.  Barsky AJ, Wyshak G, Klerman GL, Latham KS. The prevalence of hypochondriasis in 
medical outpatients. Soc Psychiatry Psychiat Epidemiol 1990; 25:  89-94. 
4. Tyrer H, Ali L, Cooper F, Seivewright P, Bassett P, & Tyrer P (2012). The Schedule for 
Evaluating Persistent Symptoms (SEPS): a new method of recording medically unexplained 
symptoms.  Int J soc Psychiatr 2013; 59: 281-7.  
5. Barsky AJ, Orav EJ, Bates DW. Somatization increases medical utilization and costs  
independent of psychiatric  and medical comorbidity. Arch Gen Psychiatry 2005; 62: 903-10. 
6. Olatunji BO, Cisler JM, Deacon BJ. Efficacy of cognitive behavioral therapy for anxiety 
disorders: a review of meta-analytic findings. Psychiatr Clin North Am 2010;33: 557-77. 
 7. Barsky AJ, Ahern DK. Cognitive behavior therapy for hypochondriasis: a randomized 
controlled trial. JAMA 2004 ; 291: 1464-70. 
8. Clark DM, Salkovskis PM, Hackmann A, Wells A, Fennell M, Ludgate ., Ahmad S, Richards 
HC,Gelder M:   Two psychological treatments for hypochondriasis: a randomized controlled 
trial. Br J Psychiatry 1998,  173: 218-25. 
9. Sørensen P, Birket-Smith M, Wattar U, Buemann I, Salkovskis P. A randomized clinical trial 
of cognitive behavioural therapy versus short-term psychodynamic psychotherapy versus no 
intervention for patients with hypochondriasis. Psychol Med 2011; 41: 431-41. 
10.  Seivewright H,  Green J,  Salkovskis P, Barrett B, Nur U, Tyrer P.  Randomised controlled 
trial of cognitive behaviour therapy in the treatment of health anxiety in a genitourinary 
medicine clinic. Br J Psychiatry 2008,  192: 332-7. 
11. Salkovskis P, Warwick HMC, Deale AC. (2003).  Cognitive-behavioural treatment for 
severe and persistent health anxiety (hypochondriasis).   Brief Treatment and Crisis 
Intervention 2003; 3:  353-68.  
12. Salkovskis PM, Rimes KA, Warwick HMC, Clark DM:  The Health Anxiety Inventory: 
development and validation of scales for the measurement of health anxiety and 
hypochondriasis. Psychol Med 2002, 32: 843-53. 
13. Zigmond AS, Snaith RP:  The Hospital Anxiety and Depression Scale. Acta Psychiat Scand 
1983, 57: 361-70. 
14. EuroQol Group. EuroQol - a new facility for the measurement of health-related quality of 
life. Health Policy 1990, 16: 199-208. 
15. Tyrer P,  Nur U, Crawford M, Karlsen S, McLean C, Rao B,  Johnson T.  The Social 
Functioning Questionnaire: a rapid and robust measure of perceived functioning. Int J Soc 
Psychiatr 2005; 51: 265-275. 
16. First MB, Spitzer RL, Gibbon M.,Williams, JB: Structured Clinical Interview for the DSM-IV 
Axis I Disorders. Washington DC: American Psychiatric Press; 1996. 
17. Young J, Beck AT (1980).  Cognitive Therapy Scale Rating Manual. Psychotherapy 
Research Unit, University of Pennsylvania, Philadelphia, USA.  
18. Barrett B, Byford S, Crawford M, Patton R, Drummond C, Henry J, Touquet R.  Cost-
effectiveness of referral to an alcohol health worker in patients attending an accident and 
emergency department: a decision-making approach. Drug Alcohol Depend 2006,  81: 47-54. 
19. Curtis L. Unit costs of health and social care 2010. Canterbury: PSSRU, University of Kent; 
2011. 
20.  British Medical Association & Royal Pharmaceutical Society of Great Britain 2010. BNF 
59. London: BMJ Books/Pharmaceutical Press. 
21.  Department of Health. NHS Reference Costs. London: Department of Health, 2011. 
22. National Institute for Health and Clinical Excellence 2008, Guide to the methods of 
technology appraisal, London: NICE 2008. 
23. Tyrer P, Cooper S, Tyrer H, Salkovskis P, Crawford M, Green J, Smith G, Reid S, 
Dupont S, Murphy D, Byford S, Wang D, Barrett B. CHAMP: Cognitive behaviour therapy for 
health anxiety in medical patients: a randomised controlled trial. BMC Psychiatry 2011; 11: 
99. 
24. Barber JA, Thompson SG . Analysis and interpretation of cost data in randomised 
controlled trials: review of published studies. BMJ 1998;  317: 1195-1200 
25. Efron B, Tibshirani R . An introduction to the bootstrap New York: Chapman and Hall, 
1993. 
 
26. Hedman E, Andersson G, Andersson E, Ljótsson B, Rück C, Asmundson GJ, Lindefors N. 
Internet-based cognitive-behavioural therapy for severe health anxiety: randomised 
controlled trial. Br J Psychiatry 2011 ;198:230-6. 
27. Hedman, E., Andersson, E., Lindefors, N., Andersson, G., Ruck, C., & Ljotsson, B. (2013). 
Cost-effectiveness and long-term effectiveness of internet-based cognitive behaviour 
therapy for severe health anxiety. Psychological Medicine, 43(2), 363-374. 
2827. Tyrer PJ . Relevance of bodily feelings in emotion. Lancet 1973; 301: 915-6. 
 
  
  
 
 Figure 2: Mean change in health anxiety score (±SE) by treatment 
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 Table 1: Baseline characteristics of patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Characteristics 
CBT-HA  
(N=219) 
Standard Care 
(N=225) 
Age (year) 50.3(13.6) 47.0(13.4) 
Gender   
  Female 113(51.6%) 123(54.7%) 
  Male 106(48.4%) 102(45.3%) 
Ethnicity   
  White British 145(67.8%) 151(68.0%) 
  White other 26(12.1%) 18(8.1%) 
  Black/Black British: African 6(2.8%) 9(4.1%) 
  Black/Black British: Caribbean 5(2.3%) 7(3.2%) 
  Asian/Asian British 15(7.0%) 23(10.4%) 
  Asian/Asian British: Other 8(3.7%) 8(3.6%) 
  Arab/Middle East 7(3.3%) 4(1.8%) 
  Chinese/Far East 2(0.9%) 2(0.9%) 
Hospital   
  Chelsea and Westminster Hospital, London 26(11.9%) 23(10.2%) 
  Charing Cross Hospital, London 31(14.2%) 26(11.6%) 
  Hillingdon Hospital, Middlesex 56(25.6%) 63(28.0%) 
  Kings Mill Hospital, Nottinghamshire 70(32.0%) 74(32.9%) 
  St Marys Hospital, London 36(16.4%) 39(17.3%) 
Clinic type   
  Cardiology 53(24.2%) 57(25.3%) 
  Endocrinology 41(18.7%) 43(19.1%) 
  Gastroenterology 77(35.2%) 72(32.0%) 
  Neurology 20(9.1%) 22(9.8%) 
  Respiratory medicine 28(12.8%) 31(13.8%) 
HAI Score 24.9(4.2) 25.1(4.5) 
Data are number (%) or mean (SD);   
  
  
 
  
  
Table 2. Summary statistics and results from mixed model analysis of change in outcomes from baseline  
 
 
 
Summary statistics  
N, mean improvement from 
baseline (SD) Results from mixed model analysis 
Outcomes Visit CBT-HA  Standard Care  Difference (95%CI) P value 
      
Health anxiety 3 Months 205, 4.41 (7.63) 212, 2.62 (6.17) 1.79(0.48,3.10) 0.0076 
(HAI) 6 Months 197, 7.11 (7.83) 204, 2.33 (5.76) 4.86(3.53,6.18) <.0001 
 12 Months 194, 6.44 (7.47) 193, 3.20 (6.54) 2.98(1.64,4.33) <.0001 
 24 Months 190, 5.90 (7.54) 183, 3.66 (6.57) 2.05(0.70,3.41) 0.0030 
       
Generalized anxiety 6 Months 197, 2.74 (4.41) 204, 1.46 (3.89) 1.29(0.52,2.06) 0.0011 
(HADS-A) 12 Months 194, 2.80 (4.40) 192, 1.67 (4.04) 1.04(0.25,1.82) 0.0095 
 24 Months 189, 3.33 (4.57) 181, 2.07 (4.35) 1.00(0.21,1.79) 0.0137 
       
Depression 6 Months 197, 1.38 (4.32) 204, 0.51 (4.14) 0.78(-0.01,1.57) 0.0529 
 12 Months 194, 1.43 (4.44) 192, 0.43 (3.69) 0.79(-0.01,1.59) 0.0527 
 24 Months 189, 1.37 (4.95) 181, 0.51 (4.38) 0.63(-0.18,1.44) 0.1263 
       
Social function 6 Months 197, 0.42 (4.46) 204, 0.39 (3.68) 0.14(-0.63,0.92) 0.7210 
 12 Months 194, 0.57 (4.46) 192, 0.39 (3.65) 0.19(-0.60,0.98) 0.6364 
 24 Months 190, 1.06 (4.76) 182, 0.83 (3.81) 0.21(-0.58,1.01) 0.6002 
      
Health-related quality of life 6 Months 196, 0.04 (0.33) 203, 0.04 (0.35) -0.00 (-0.06,0.06) 0.9921 
(EQ-5D scores) 12 Months 194, 0.08 (0.34) 191, 0.08 (0.35) -0.00 (-0.06,0.06) 0.9736 
 24 Months 189, 0.08 (0.32) 181, 0.07 (0.34) 0.02 (-0.04,0.08) 0.5075 
      
Health-related quality of life  6 Months 189, 6.04 (29.94) 194, 2.33 (23.65) 4.32 (-0.27,8.90) 0.0649 
(EQ-5D visual analogue 12 Months 185, 7.06 (29.12) 184, 5.72 (25.20) 1.56 (-3.10,6.21) 0.5121 
scale) 24 Months 183, 9.29 (30.43) 172, 5.81 (23.42) 4.06 (-0.67,8.79) 0.0923 
 
Table 3.  Mean total cost (£) per patient over 24 months follow-up 
  
 
 CBT-HA 
(N=172) 
Standard care 
(N=170) 
    
 Mean (SD) Mean (SD) Mean difference Adjusted mean 
difference* 
95% CI* p-value* 
CBT-HA 421.51 (308.25) 0.00 (0.00) 421.51    
General Practitioner contacts 381.34 (428.83) 417.64 (586.74) -36.30    
Other Ccommunity health and 
social care contacts 
392.68 (976.43) 
774.02 (1153.36) 
473.89 (392.68) 
891.53 (16439.54) 
-81.21 
-117.50 
   
Medication  2037.33 (2760.75) 2376.74 (4487.03) -339.41    
Hospital services 3946.81 (5583.89) 4223.31 (6353.28) -276.50    
Service provided accommodation 134.52 (1025.45) 235.83 (1640.25) -101.31    
Total 7314.20 (7429.58) 7727.40 (8324.58) -413.20 -155.86 -1,446.20-1757 to 
1,757.931446.20 
0.848 
Total with missing data imputed 7594.89 (7255.25) 7707.91 (8324.58) -113.02 -304.70 -1539.03 to 929.64 0.630 
*Applying bootstrapped costs and adjusted for baseline costs 
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